Direkt zum Inhalt
Merck

C7744

Sigma-Aldrich

Combretastatin A4

≥98% (HPLC), powder

Synonym(e):

1-(3,4,5-Trimethoxyphenyl)-2-(3′-hydroxy-4′-methoxyphenyl) ethane 3,4,5-trimethoxy-3′-hydroxy-4′-methoxystilbene, 2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol, CA4

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise

Größe auswählen

5 MG
CHF 164.00
25 MG
CHF 464.00

CHF 164.00


Voraussichtliches Versanddatum28. Mai 2025


Bulk-Bestellung anfordern

Größe auswählen

Ansicht ändern
5 MG
CHF 164.00
25 MG
CHF 464.00

About This Item

Empirische Formel (Hill-System):
C18H20O5
CAS-Nummer:
Molekulargewicht:
316.35
MDL-Nummer:
UNSPSC-Code:
12352200
PubChem Substanz-ID:
NACRES:
NA.77

CHF 164.00


Voraussichtliches Versanddatum28. Mai 2025


Bulk-Bestellung anfordern

Assay

≥98% (HPLC)

Form

powder

Farbe

off-white

Löslichkeit

DMSO: >10 mg/mL

Lagertemp.

−20°C

SMILES String

COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1O

InChI

1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5-

InChIKey

HVXBOLULGPECHP-WAYWQWQTSA-N

Allgemeine Beschreibung

Combretastatin A4 belong to the class of colchicinoids compounds.[1]

Anwendung

Combretastatin A4 has been used:
  • as an anti-tubulin agent to determine the effects of isocitrate dehydrogenases (IDH1 and IDH2) proteins in G2/M phase[2]
  • to evaluate the anti-proliferative and pro-apoptotic properties of biphenyl CA4 derivatives in both 2D and 3D cancerous and non-cancerous cell models[1]
  • as a microtubule inhibitor to study its effects on motility of Ascaris suum L3 larvae[3]

Biochem./physiol. Wirkung

Combretastatin A4 is a potent microtubule targeting agent (MTA).[1]
Combretastatin A4 is a vascular disrupting agent (VDA) that targets tumor vasculature to inhibit angiogenesis.
Combretastatin A4 is a vascular disrupting agent (VDA) that targets tumor vasculature to inhibit angiogenesis. It inhibits tubulin polymerization at the colchicine-binding site of beta-tubulin. It has antitumor activity by inhibiting AKT function in human gastric cells. The inhibited AKT activation causes decreased cell proliferation, cell cycle arrest, and reduced in vitro migration/invasiveness and in vivo metastatic ability. Combretastatin A4 is a natural stilbenoid phenol.

Piktogramme

Skull and crossbonesCorrosion

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Eye Dam. 1

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 2

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Persönliche Schutzausrüstung

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 2

1 of 2

Christian Damsgaard et al.
eLife, 9 (2020-08-26)
Previously, we showed that the evolution of high acuity vision in fishes was directly associated with their unique pH-sensitive hemoglobins that allow O2 to be delivered to the retina at PO2s more than ten-fold that of arterial blood (Damsgaard et
Abundance of d-2-hydroxyglutarate in G2/M is determined by FOXM1 in mutant IDH1-expressing cells
Bala Bhaskara Rao K, et al.
Febs Letters, 593(16), 2177-2193 (2019)
Medicinal chemistry of combretastatin A4: present and future directions.
Gian Cesare Tron et al.
Journal of medicinal chemistry, 49(11), 3033-3044 (2006-05-26)
De novo identification of toxicants that cause irreparable damage to parasitic nematode intestinal cells
Jasmer DP, et al.
PLoS Neglected Tropical Diseases, 14(5), e0007942-e0007942 (2020)
Lasse Dührsen et al.
Journal of neurosurgery, 128(6), 1668-1673 (2017-07-29)
OBJECTIVE Temporal lobe epilepsy (TLE) is the most common type of pharmacoresistant focal epilepsy, for which anterior mesial temporal lobe resection (AMTLR) is a treatment option. Focal cortical dysplasia Type IIIa (FCD IIIa), a developmental lesion resulting from defects in

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.